Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis

被引：0
|
作者：
Swain, Sandra
Cortes, Javier
Xu, Binghe
Lambertini, Chiara
Essioux, Laurent
Knott, Adam
Restuccia, Eleonora
Madjar, Katrin
De Haas, Sanne Lysbet
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-11-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-11-07
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [32] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [33] Decreased PTEN expression and PIK3CA mutations in HER-2 positive breast cancer.
    Koninki, K.
    Kauraniemi, P.
    Pitkanen, J.
    Isola, J.
    Tanner, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S211 - S211
  • [34] FIRST-LINE TREATMENT IN HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER
    Yamaguchi, K.
    Ooki, A.
    Yamada, T.
    Hara, H.
    Asayama, M.
    Tada, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [35] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] IMPACT OF PIK3CA MUTATIONS AND P95HER2 EXPRESSION ON THE OUTCOME OF HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH A TRASTUZUMAB-BASED THERAPY
    Stasi, I.
    Fontana, A.
    Allegrini, G.
    Mazzanti, C.
    Lucchesi, S.
    Bona, E.
    Ferrarini, I.
    Salvadori, B.
    Falcone, A.
    Zavaglia, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [37] Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population
    Saikia K.K.
    Panigrahi M.K.
    Mehta A.
    Kumar D.
    Indian Journal of Surgical Oncology, 2018, 9 (3) : 381 - 386
  • [38] Analysis of PIK3CA Mutations in Breast Cancer Subtypes
    Arsenic, Ruza
    Lehmann, Annika
    Budczies, Jan
    Koch, Ines
    Prinzler, Judith
    Kleine-Tebbe, Anke
    Schewe, Christiane
    Loibl, Sibylle
    Dietel, Manfred
    Denkert, Carsten
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (01) : 50 - 56
  • [39] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
    Hu, Wenyu
    Yang, Jixin
    Zhang, Ze
    Xu, Dongdong
    Li, Nanlin
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (02) : 247 - +
12345